Cargando…
How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved?
Low-molecular-weight heparin (LMWH) is suggested for thromboprophylaxis in pregnant women with previous venous thromboembolism (VTE). Anyway, there is only limited amount of studies evaluating the effect of LMWH on hemostatic parameters during pregnancy of patients with previous VTE and the need of...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894622/ https://www.ncbi.nlm.nih.gov/pubmed/35225706 http://dx.doi.org/10.1177/10760296211070004 |
_version_ | 1784662717949280256 |
---|---|
author | Stanciakova, Lucia Dobrotova, Miroslava Holly, Pavol Zolkova, Jana Vadelova, Lubica Skornova, Ingrid Ivankova, Jela Samos, Matej Bolek, Tomas Grendar, Marian Danko, Jan Kubisz, Peter Stasko, Jan |
author_facet | Stanciakova, Lucia Dobrotova, Miroslava Holly, Pavol Zolkova, Jana Vadelova, Lubica Skornova, Ingrid Ivankova, Jela Samos, Matej Bolek, Tomas Grendar, Marian Danko, Jan Kubisz, Peter Stasko, Jan |
author_sort | Stanciakova, Lucia |
collection | PubMed |
description | Low-molecular-weight heparin (LMWH) is suggested for thromboprophylaxis in pregnant women with previous venous thromboembolism (VTE). Anyway, there is only limited amount of studies evaluating the effect of LMWH on hemostatic parameters during pregnancy of patients with previous VTE and the need of secondary thromboprophylaxis. We therefore provide results of prospective and longitudinal assessment of changes in hemostasis in high-risk pregnant women at four times during pregnancy (T1–T4) and one time after the postpartum period (T5) used for individualized modification of thromboprophylaxis. In this study, the results of coagulation factor VIII (FVIII) and protein S (PS) activity, ProC Global ratio and anti-Xa activity were evaluated. Despite the thromboprophylaxis, an increased predisposition to thromboembolic complications was detected (significant increase in FVIII activity and decrease in PS function, ProC Global ratio not normalized even after the postpartum period – p < .0001 between controls and T5 for PS and ProC Global). These results indicate that hemostasis may not be restored even 6 to 8 weeks after delivery and pose the question when is it safe to withdraw the anticoagulant thromboprophylaxis in high-risk patients with prior VTE. |
format | Online Article Text |
id | pubmed-8894622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88946222022-03-05 How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved? Stanciakova, Lucia Dobrotova, Miroslava Holly, Pavol Zolkova, Jana Vadelova, Lubica Skornova, Ingrid Ivankova, Jela Samos, Matej Bolek, Tomas Grendar, Marian Danko, Jan Kubisz, Peter Stasko, Jan Clin Appl Thromb Hemost Original Manuscript Low-molecular-weight heparin (LMWH) is suggested for thromboprophylaxis in pregnant women with previous venous thromboembolism (VTE). Anyway, there is only limited amount of studies evaluating the effect of LMWH on hemostatic parameters during pregnancy of patients with previous VTE and the need of secondary thromboprophylaxis. We therefore provide results of prospective and longitudinal assessment of changes in hemostasis in high-risk pregnant women at four times during pregnancy (T1–T4) and one time after the postpartum period (T5) used for individualized modification of thromboprophylaxis. In this study, the results of coagulation factor VIII (FVIII) and protein S (PS) activity, ProC Global ratio and anti-Xa activity were evaluated. Despite the thromboprophylaxis, an increased predisposition to thromboembolic complications was detected (significant increase in FVIII activity and decrease in PS function, ProC Global ratio not normalized even after the postpartum period – p < .0001 between controls and T5 for PS and ProC Global). These results indicate that hemostasis may not be restored even 6 to 8 weeks after delivery and pose the question when is it safe to withdraw the anticoagulant thromboprophylaxis in high-risk patients with prior VTE. SAGE Publications 2022-02-28 /pmc/articles/PMC8894622/ /pubmed/35225706 http://dx.doi.org/10.1177/10760296211070004 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Stanciakova, Lucia Dobrotova, Miroslava Holly, Pavol Zolkova, Jana Vadelova, Lubica Skornova, Ingrid Ivankova, Jela Samos, Matej Bolek, Tomas Grendar, Marian Danko, Jan Kubisz, Peter Stasko, Jan How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved? |
title | How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients
be Improved? |
title_full | How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients
be Improved? |
title_fullStr | How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients
be Improved? |
title_full_unstemmed | How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients
be Improved? |
title_short | How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients
be Improved? |
title_sort | how can secondary thromboprophylaxis in high-risk pregnant patients
be improved? |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894622/ https://www.ncbi.nlm.nih.gov/pubmed/35225706 http://dx.doi.org/10.1177/10760296211070004 |
work_keys_str_mv | AT stanciakovalucia howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT dobrotovamiroslava howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT hollypavol howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT zolkovajana howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT vadelovalubica howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT skornovaingrid howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT ivankovajela howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT samosmatej howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT bolektomas howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT grendarmarian howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT dankojan howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT kubiszpeter howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved AT staskojan howcansecondarythromboprophylaxisinhighriskpregnantpatientsbeimproved |